0001437749-20-024903.txt : 20201204
0001437749-20-024903.hdr.sgml : 20201204
20201204194209
ACCESSION NUMBER: 0001437749-20-024903
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201202
FILED AS OF DATE: 20201204
DATE AS OF CHANGE: 20201204
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kennedy Giulia C
CENTRAL INDEX KEY: 0001769333
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36156
FILM NUMBER: 201371086
MAIL ADDRESS:
STREET 1: 338 MAIN STREET #26E
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94105
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERACYTE, INC.
CENTRAL INDEX KEY: 0001384101
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 205455398
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6000 SHORELINE COURT, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 243-6300
MAIL ADDRESS:
STREET 1: 6000 SHORELINE COURT, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: CALDEROME INC
DATE OF NAME CHANGE: 20061219
4
1
rdgdoc.xml
FORM 4
X0306
4
2020-12-02
0001384101
VERACYTE, INC.
VCYT
0001769333
Kennedy Giulia C
6000 SHORELINE COURT
SUITE 300
SOUTH SAN FRANCISCO
CA
94080
1
Chief Scientific & Med Officer
Common Stock
2020-12-02
4
F
0
540
55.08
D
78859
D
Common Stock
2020-12-04
4
M
0
5312
9.05
A
84171
D
Common Stock
2020-12-04
4
M
0
4406
5.98
A
88577
D
Common Stock
2020-12-04
4
M
0
3750
20.21
A
92327
D
Common Stock
2020-12-04
4
S
0
3642
55.777
D
88685
D
Common Stock
2020-12-04
4
S
0
4279
56.8555
D
84406
D
Common Stock
2020-12-04
4
S
0
6094
57.5536
D
78312
D
Stock Option (right to buy)
9.05
2020-12-04
4
M
0
5312
0
D
2027-03-02
Common Stock
5312
5313
D
Stock Option (right to buy)
5.98
2020-12-04
4
M
0
4406
0
D
2028-03-01
Common Stock
4406
22032
D
Stock Option (right to buy)
20.21
2020-12-04
4
M
0
3750
0
D
2029-02-27
Common Stock
3750
33750
D
The reporting person is reporting the withholding of 292 and 248 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 587 and 500 Restricted Stock Units, respectively granted on March 2, 2018 and February 28, 2019, respectively, and does not represent a sale by the reporting person.
The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020.
Represents weighted average sales price. Sale prices for the transactions range from $55.27 to $56.13. Detailed information regarding the number of shares sold at each separate price will be provided to the
SEC, the issuer or a shareholder upon request.
Represents weighted average sales price. Sale prices for the transactions range from $56.28 to $57.11. Detailed information regarding the number of shares sold at each separate price will be provided to the
SEC, the issuer or a shareholder upon request.
Represents weighted average sales price. Sale prices for the transactions range from $57.31 to $57.90. Detailed information regarding the number of shares sold at each separate price will be provided to the
SEC, the issuer or a shareholder upon request.
The option becomes exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous
service thereafter.
The option becomes exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous
service thereafter.
The option becomes exercisable as to 25% of the shares on February 28, 2020, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous
service thereafter.
/s/ Keith Kennedy, as Attorney-in-fact
2020-12-04